Evidence map›Paper›PMID 41335382›Full record

ReviewCurrent nutrition reports2025

The Role of Mediterranean Diet and Intermittent Fasting in Modulating Inflammation and Clinical Biochemistry Markers in Hereditary Cancer Syndromes: A Review.

Francesco Cacciabaudo, Giulia Accardi, Francesca Carta, Salvatore Tarantino, Giuseppe Annunziata, Tancredi Didier Bazan Russo, Paula Silva, Giuseppina Candore, Antonio Russo, Marcello Ciaccio

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Current nutrition reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Francesco Cacciabaudo *Department of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0009-0004-9886-2385
Giulia Accardi *Laboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, 90127, Italy. giulia.accardi@unipa.it.ORCID http://orcid.org/0000-0003-3565-9529
Francesca CartaLaboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0009-0001-4491-9807
Salvatore TarantinoDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0009-0001-2173-5239
Giuseppe AnnunziataDepartment of Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.ORCID http://orcid.org/0000-0002-1922-662X
Tancredi Didier Bazan RussoDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0009-0007-5595-3924
Paula SilvaUniversity of Porto (U. Porto), Porto, Portugal.ORCID http://orcid.org/0000-0001-7204-6006
Giuseppina CandoreLaboratory of Immunopathology and Immunosenescence, Department of Biomedicine, Neurosciences and Advanced Diagnostics, University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0002-9966-934X
Antonio RussoDepartment of Precision Medicine in Medical, Surgical and Critical Care (Me.Pre.C.C.), University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0002-4370-2008
Marcello CiaccioDepartment of Biomedicine, Neurosciences and Advanced Diagnostics, Institute of Clinical Biochemistry, Clinical Molecular Medicine, and Clinical Laboratory Medicine, University of Palermo, Palermo, 90127, Italy.ORCID http://orcid.org/0000-0001-6120-9041

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThis literature review of clinical and preclinical studies aimed to analyse the latest evidence on the Mediterranean diet (MD) and intermittent fasting (IF) to prevent or delay strategies for the onset of cancer in patients with hereditary cancer syndromes, correlating the data about some nutritional, clinical biochemical, and inflammatory biomarkers (e.g. CRP, IL-6, insulin, and IGF-1). Preliminary evidence from the literature suggests that MD and IF can favourably modulate markers of chronic inflammation and metabolism, potentially reducing the risk of cancer. RECENT

findingsCancer risk increases significantly throughout life in patients with hereditary cancer syndromes such as BRCA1/2. Evidence suggests the role of lifestyle, especially nutrition, in delaying the onset of these diseases. Although existing studies point to promising roles for MD and IF in managing cancer risk, additional research is needed to clarify their long-term effects and define personalised guidelines for individuals with hereditary cancer syndromes. Preliminary data suggest that the MD and IF may help delay cancer onset in hereditary syndromes by modulating inflammation and metabolism. More studies are needed to confirm long-term benefits and guide personalized prevention.

Indexed as

Diet, MediterraneanFastingInflammationIntermittent FastingNeoplastic Syndromes, HereditaryBiomarkersHumansInsulin-Like Growth Factor IInterleukin-6BiomarkersInsulin-Like Growth Factor IInterleukin-6BiomarkersBRCAHereditary cancer syndromesInflammationIntermittent fastingMediterranean diet

Identifiers

PMID41335382
PMCPMC12675562

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.